- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Schrodinger Shifts to Hosted Software, Partners with Anthropic on AI Integration
The medical AI company aims to transition 75% of its software contracts to cloud-based models within 3 years.
Apr. 19, 2026 at 8:51pm
Got story updates? Submit your updates here. ›
Schrodinger's strategic shift to cloud-based software and AI integration aims to provide its biotech and pharmaceutical clients with more powerful tools to accelerate drug discovery.NYC TodaySchrodinger Inc (NASDAQ:SDGR), a leading medical AI company, is making strategic moves to shift 75% of its software contracts to hosted cloud-based models within the next three years. The company is also partnering with Anthropic and other AI firms to integrate advanced AI capabilities into its drug discovery and material science software platforms, aiming to enhance user efficiency and expand its customer base.
Why it matters
Schrodinger's shift to hosted software models and AI integration aligns with growing customer demand for cloud-based solutions and advanced computational tools in the biotech and pharmaceutical industries. By leveraging AI, Schrodinger aims to provide its clients with more powerful software to accelerate drug discovery and reduce research costs, giving the company a competitive edge in the rapidly evolving medical AI market.
The details
Schrodinger's management discussed these strategic initiatives during the 2026 KeyBanc Capital Markets Healthcare Forum on March 17. The company reported Q4 2025 revenue of $87.2 million, a 1.2% year-over-year decline, but beat analyst forecasts. Drug discovery revenue more than doubled year-over-year to $18 million, even as software revenue decreased 13% due to the shift in recognition. Schrodinger's partnership with Eli Lilly, announced in January, will integrate Lilly's AI-powered TuneLab platform into Schrodinger's cloud-based LiveDesign platform, allowing clients to access advanced AI-driven drug discovery tools directly.
- Schrodinger presented its strategic plans at the 2026 KeyBanc Capital Markets Healthcare Forum on March 17.
- Schrodinger announced its partnership with Eli Lilly on January 9, 2026.
The players
Schrodinger Inc
A leading medical AI company that develops software and computational tools used in drug discovery and material science.
Anthropic
An AI research company that Schrodinger is partnering with to integrate advanced AI capabilities into its software platforms.
Eli Lilly
A pharmaceutical company that has partnered with Schrodinger to integrate Lilly's AI-powered TuneLab platform into Schrodinger's cloud-based LiveDesign platform.
What’s next
Schrodinger will continue to work with Anthropic and other AI companies to further integrate advanced AI capabilities into its software platforms, aiming to enhance user efficiency and expand its customer base in the biotech and pharmaceutical industries.
The takeaway
Schrodinger's strategic shift to hosted software models and AI integration positions the company to better meet growing customer demand for cloud-based solutions and advanced computational tools in the rapidly evolving medical AI market, potentially giving it a competitive edge in accelerating drug discovery and reducing research costs for its clients.
